As new therapies for idiopathic pulmonary fibrosis (IPF) emerge, healthcare stakeholders must navigate the balance between innovation and evidence-based coverage decisions. This webinar brings together clinical, regulatory, and payer perspectives to examine how value is assessed in rare diseases like IPF, beyond traditional endpoints. Topics include the implications of breakthrough designations, the role of real-world evidence, and novel measures of clinical benefit.

Learning objectives: 

1. How stakeholders can balance the urgency of innovation in idiopathic pulmonary fibrosis (IPF) with the need for clinically meaningful evidence to inform coverage decisions. 
2. Explore how value is assessed in payer decision-making for rare diseases, like IPF, beyond traditional trial endpoints, with consideration for breakthrough designation, real-world impact, and nontraditional measures of clinical benefit. 
3. Identify strategies to optimize patient access while ensuring appropriate use of emerging IPF therapies through collaborative approaches that align clinical value with payer expectations. 

This is a non-CME event. By registering for this program, you consent to share your registration information with the program's sponsor.